West Pharmaceutical Services, Inc. (WST) Valuation
Historical valuation analysis based on 1280 data points (2021-09-13 to 2026-10-16)
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging componen...
West Pharmaceutical Services, Inc. (WST) currently trades at a P/E ratio of 47.84 (historical range: 25.20–66.74, median: 43.06), placing it at the 72th percentile — above its historical average, P/S ratio of 8.12 (range: 4.80–13.74, 52th percentile — near its historical average), EV/EBITDA of 38.86 (range: 19.50–57.00, 64th percentile).
West Pharmaceutical Services, Inc. trades above its historical valuation range, with most metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 47.84 | 43.06 | 72th | above its historical average |
| P/S Ratio | 8.12 | 8.04 | 52th | near its historical average |
| EV/EBITDA | 38.86 | 36.25 | 64th | above its historical average |
| FCF Yield | 1.62% | 1.62% | 49th | near its historical average |
West Pharmaceutical Services, Inc. (WST) Valuation & P/E History
West Pharmaceutical Services, Inc. (WST) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry currently trading at $384.02 with a market capitalization of $27.0 billion. This page provides historical valuation analysis for WST based on 1280 data points covering 2021-09-13 to 2026-10-16. The P/E ratio of 47.84 is above the historical median of 43.06, placing WST at the 72th percentile of its valuation range. The P/S ratio of 8.12 compares to a median of 8.04.
WST Valuation Metrics & Historical Range
The valuation table above shows West Pharmaceutical Services, Inc.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether WST is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests WST is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for West Pharmaceutical Services, Inc..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is WST Overvalued or Undervalued?
West Pharmaceutical Services, Inc. trades above its historical valuation range, with most metrics above their median levels. The overall valuation percentile of 63 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive WST is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full WST analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.WST trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.